Patiromer With or Without Food for the Treatment of Hyperkalemia

Approximately 110 eligible participants with hyperkalemia will be randomly assigned to
receive a patiromer starting dose of 8.4- g/day, either with or without food.

All participants will undergo a screening period (1 day) to determine eligibility for study
entry. Eligible participants will be treated for 4 weeks and followed for 2 weeks after
completing the patiromer treatment. There are six planned clinic visits during the Treatment
Period and two planned visits after the last dose of patiromer during the Follow-up Period.

The dose of patiromer may be increased or decreased (titrated) based on participants'
individual potassium response.

Key Inclusion Criteria:

- Potassium concentration > 5.0 mEq/L from two blood draws at Screening

- Stable RAASi medication, if taking

- Medications taken on a chronic basis are given once daily or twice daily

- Informed consent given

Key Exclusion Criteria:

- Expected need for dialysis

- Major organ transplant

- History of conditions associated with pseudohyperkalemia

- History of swallowing disorder, gastroparesis, bariatric surgery, bowel obstruction or
severe gastrointestinal disorders or major gastrointestinal surgery

- Cancer or unstable medical condition